New exploration in clinical treatment: All-trans retinoic acid plus low-dose rituximab in the treatment of adult immune thrombocytopenia
-
摘要: 免疫性血小板减少症是一种孤立的血小板减少症，其特点是免疫失耐受介导的血小板破坏增多和血小板生成减少。其治疗包括皮质类固醇、静脉注射免疫球蛋白、利妥昔单抗、血小板生成素受体激动剂、免疫抑制剂和脾切除术。尽管目前的疗法对2/3以上的患者有效，但仍有一些患者无法获得长期疗效。本文介绍了全反式维甲酸联合小剂量CD20单克隆抗体治疗成人免疫性血小板减少症的疗效、安全性以及应用前景。Abstract: Immune thrombocytopenia is an isolated thrombocytopenia characterized by the increased platelet destruction and decreased platelet production mediated by the loss of immune tolerance. Its treatment includes corticosteroids, intravenous immunoglobulin, rituximab, thrombopoietin receptor agonists, immunosuppressants, and splenectomy. Although current therapies are effective for over two-thirds of patients, there are still some patients who cannot achieve long-term efficacy. This article introduces the efficacy, safety, and application prospects of all-trans retinoic acid combined with low-dose CD20 monoclonal antibody in the treatment of adult immune thrombocytopenia.
-
Key words:
- immune thrombocytopenia /
- all-trans retinoic acid /
- rituximab /
- immunotherapy
-
-
[1] Cooper N, Ghanima W. Immune Thrombocytopenia[J]. N Engl J Med, 2019, 381(10): 945-955. doi: 10.1056/NEJMcp1810479
[2] McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J]. Blood, 2004, 103(4): 1364-1369. doi: 10.1182/blood-2003-08-2672
[3] Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J]. Nat Med, 2003, 9(9): 1123-1124. doi: 10.1038/nm921
[4] Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment[J]. Blood, 1993, 81(5): 1246-1250. doi: 10.1182/blood.V81.5.1246.1246
[5] Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports[J]. Am J Hematol, 2010, 85(3): 174-180. doi: 10.1002/ajh.21616
[6] Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France[J]. Blood, 2014, 124(22): 3308-3315. doi: 10.1182/blood-2014-05-578336
[7] Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia[J]. Blood Adv, 2019, 3(23): 3829-3866. doi: 10.1182/bloodadvances.2019000966
[8] Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood Adv, 2019, 3(22): 3780-3817. doi: 10.1182/bloodadvances.2019000812
[9] Depré F, Aboud N, Mayer B, et al. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice[J]. PLoS One, 2018, 13(6): e0198184. doi: 10.1371/journal.pone.0198184
[10] Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood[J]. Lancet, 1981, 317(8232): 1228-1231. doi: 10.1016/S0140-6736(81)92400-4
[11] Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?[J]. Nat Rev Immunol, 2013, 13(3): 176-189. doi: 10.1038/nri3401
[12] Cines DB, Blanchette VS. Immune Thrombocytopenic Purpura[J]. N Engl J Med, 2002, 346(13): 995-1008. doi: 10.1056/NEJMra010501
[13] Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia[J]. Blood, 1988, 72(2): 567-572. doi: 10.1182/blood.V72.2.567.567
[14] Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid[J]. Blood, 1981, 57(6): 1000-1004. doi: 10.1182/blood.V57.6.1000.1000
[15] Feng Q, Xu M, Yu YY, et al. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia[J]. J Thromb Haemostasis, 2017, 15(9): 1845-1858. doi: 10.1111/jth.13767
[16] Zhu X, Wang Y, Jiang Q, et al. All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1β loop[J]. Haematologica, 2019, 104(8): 1661-1675. doi: 10.3324/haematol.2018.204446
[17] Dai L, Zhang R, Wang Z, et al. Efficacy of immunomodulatory therapy with all-trans retinoid acid in adult patients with chronic immune thrombocytopenia[J]. Thromb Res, 2016, 140: 73-80. doi: 10.1016/j.thromres.2016.02.013
[18] Feng FE, Feng R, Wang M, et al. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial[J]. Lancet Haematol, 2017, 4(10): e487-e496. doi: 10.1016/S2352-3026(17)30170-9
[19] Huang QS, Liu Y, Wang JB, et al. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial[J]. Lancet Haematol, 2021, 8(10): e688-e699. doi: 10.1016/S2352-3026(21)00240-4
[20] Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab[J]. Blood, 2008, 112(4): 1147-1150. doi: 10.1182/blood-2007-12-129262
[21] Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura[J]. Blood, 2007, 110(8): 2924-2930. doi: 10.1182/blood-2007-02-068999
[22] Lambert M, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia[J]. Blood, 2017, 129(21): 2829-2835. doi: 10.1182/blood-2017-03-754119
[23] Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura[J]. Blood, 2001, 98(4): 952-957. doi: 10.1182/blood.V98.4.952
[24] Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia[J]. Am J Hematol, 2012, 87(9): 886-889. doi: 10.1002/ajh.23272
[25] Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J]. Blood, 2012, 119(25): 5989-5995. doi: 10.1182/blood-2011-11-393975
[26] Li Y, Shi Y, He Z, et al. The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis[J]. Platelets, 2019, 30(6): 690-697. doi: 10.1080/09537104.2019.1624706
[27] Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out[J]. Blood, 2018, 131(11): 1172-1182. doi: 10.1182/blood-2017-09-742353
[28] Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia(the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9978): 1653-1661. doi: 10.1016/S0140-6736(14)61495-1
[29] Ferraro AJ, Drayson MT, Savage COS, et al. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab[J]. Eur J Immunol, 2008, 38(1): 292-298. doi: 10.1002/eji.200737557
[30] Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase Ⅰ/Ⅱ dose-escalation trial of rituximab[J]. Arthritis Rheu, 2004, 50(8): 2580-2589. doi: 10.1002/art.20430
[31] Avilés A, Talavera A, Díaz-Maqueo JC, et al. Evaluation on a Six-Dose Treatment of Anti CD 20 Monoclonal Antibody in Patients with Refractory Follicular Lymphoma[J]. Cancer Biother Radiopharm, 2001, 16(2): 159-162.
[32] Avilés A, León MI, Díaz-Maqueo JC, et al. Rituximab in the Treatment of Refractory Follicular Lymphoma-Six Doses Are Better Than Four[J]. J Hematother Stem Cell Res, 2001, 10(2): 313-316. doi: 10.1089/15258160151135088
[33] Vital EM, Dass S, Buch MH, et al. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial[J]. Ann Rheum Dis, 2015, 74(6): 1195-1201. doi: 10.1136/annrheumdis-2013-204544
[34] Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment[J]. Blood, 2020, 135(7): 472-490. doi: 10.1182/blood.2019003599
[35] Wu YJ, Liu H, Zeng QZ, et al. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP[J]. Blood, 2022, 139(3): 333-342. doi: 10.1182/blood.2021013393
-
计量
- 文章访问数: 369
- PDF下载数: 253
- 施引文献: 0
下载: